

# Myocarditis/pericarditis after mRNA COVID-19 vaccination



A small number of cases of myocarditis and pericarditis (inflammation in the heart) have been reported in Ontario.



Most cases occurred in teens and young adult males after their second shot. under 25 years of age after their second dose.



Cases had mild illness, responded well to treatment and symptoms improved quickly.



If you experience chest pain, trouble breathing, or irregular heartbeat in the days after vaccination, seek medical attention.



Pfizer-BioNTech is the preferred vaccine for those under 25. There is an increased risk of myocarditis/pericarditis with Moderna vaccination in those under 25.

COVID-19 infection can cause heart damage. While the Moderna vaccine is approved for individuals under 25, Pfizer is the preferred vaccine product for this age group. All individuals 18-25 who choose to receive Moderna must provide informed consent and understand the increased risk of myocarditis/pericarditis for their age group. Vaccination is highly recommended: the benefits of vaccination outweigh the potential risks.

September 2021